Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Treasury Shares (2016 - 2026)

Anika Therapeutics has reported Treasury Shares over the past 17 years, most recently at $230791.0 for Q1 2026.

  • Quarterly Treasury Shares fell 20.63% to $230791.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $230791.0 through Mar 2026, down 20.63% year-over-year, with the annual reading at $953713.0 for FY2025, 14.0% up from the prior year.
  • Treasury Shares was $230791.0 for Q1 2026 at Anika Therapeutics, down from $953713.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $957338.0 in Q2 2025 and troughed at $53000.0 in Q2 2024.
  • The 5-year median for Treasury Shares is $684163.5 (2022), against an average of $553114.9.
  • Year-over-year, Treasury Shares crashed 72.16% in 2023 and then skyrocketed 1706.3% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $675405.0 in 2022, then crashed by 72.16% to $188000.0 in 2023, then surged by 344.98% to $836562.0 in 2024, then rose by 14.0% to $953713.0 in 2025, then plummeted by 75.8% to $230791.0 in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Treasury Shares are $230791.0 (Q1 2026), $953713.0 (Q4 2025), and $957338.0 (Q2 2025).